Endometrial Safety of a Low Dose Continuous Combined 17 -Estradiol/Dydrogesterone Hormone Replacement Regimen (E2 0.5 mg/ D 2.5 mg) in Postmenopausal Women - A One-Year, Open Label, Multi-Center Study.

Trial Profile

Endometrial Safety of a Low Dose Continuous Combined 17 -Estradiol/Dydrogesterone Hormone Replacement Regimen (E2 0.5 mg/ D 2.5 mg) in Postmenopausal Women - A One-Year, Open Label, Multi-Center Study.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Apr 2010

At a glance

  • Drugs Estradiol/dydrogesterone (Primary)
  • Indications Menopausal syndrome; Menopause
  • Focus Adverse reactions; Registrational
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 11 Mar 2008 Status changed from discontinued to completed, as reported by ClinicalTrials.gov.
    • 27 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top